|
original article |
Date |
Title |
Authors All Authors |
1 |
[GO] |
2023―Mar―13 |
The use of dornase alfa in patients with COVID-19 |
Dinesh Sangarran Ramachandram, Chia Siang Kow, Syed Shahzad Hasan |
2 |
[GO] |
2022―Oct―03 |
40 An update from Minnesota on the seroprevalence of COVID-19 immunoglobulin G in our adult population |
K. Mahan, J. Billings, S. Kiel, J. Dunitz |
3 |
[GO] |
2022―Oct―03 |
50 Multi-center cohort study exploring the impact of the first U.K. COVID-19 lockdown on nebulizer use in adults with cystic fibrosis in the CFHealthHub learning health system |
L. Lai, R. Sandler, S. Dawson, Z. Hoo, T. Daniels, M. Hutchings, et al. (+3) M. Sperrin, M. Wildman, C. Echevarria |
4 |
[GO] |
2022―Oct―03 |
67 Implementation of a health screening process for cystic fibrosis care during the COVID-19 pandemic |
B. Evangelista, R. Murray, R. List, D. Albon, H. Bruschwein, M. Compton, et al. (+3) D. Jennings, R. Turner, L. Somerville |
5 |
[GO] |
2022―Oct―03 |
48 Longitudinal outcomes of adults and children with cystic fibrosis during the COVID-19 pandemic |
M. Doumit, S. Chuang, P. Middleton, H. Selvadurai, S. Sivam, R. Ruseckaite, et al. (+5) S. Ahern, K. Mallitt, V. Pacey, K. Gray, A. Jaffe |
6 |
[GO] |
2022―Oct―03 |
37 Trends in Canadian cystic fibrosis health care use amidst the COVID-19 pandemic |
T. Le, S. Cheng, J. Wallenburg, A. Stephenson |
7 |
[GO] |
2022―Oct―03 |
31 Sleep disturbance and school engagement in children with cystic fibrosis during the COVID-19 pandemic |
B. Wisniewski, K. Swegheimer, T. Boat, M. Hjelm |
8 |
[GO] |
2022―Oct―03 |
62 Lessons learned from the experience of patients and parents of adaptations in cystic fibrosis care during COVID-19 pandemic in France |
D. Pougheon, A. Chansard, A. Fanchini, S. Therouanne, P. Lombrail |
9 |
[GO] |
2022―Oct―03 |
254 Patient perception of the impact of elexacaftor/tezacaftor/ivacaftor and the COVID-19 pandemic on physical and mental health |
C. Sakon, H. Vogt, C. Brown, E. Tillman |
10 |
[GO] |
2022―Oct―03 |
221 COVID-19: Evolution of nutritional status in children with cystic fibrosis at the Federico Gomez Children's Hospital in Mexico |
I. Núñez Barrera, M. Sánchez, J. Lezana Fernández, M. Reyes Apodaca, P. Almada |
11 |
[GO] |
2022―Oct―03 |
51 Outcomes after SARS-CoV-2 infection in Canadians with cystic fibrosis: Analyses using the Canadian Cystic Fibrosis Registry |
S. Cheng, T. Le, J. Wallenburg, J. Sykes, A. Stephenson |
12 |
[GO] |
2022―Oct―03 |
27 Effect of SARS-CoV-2 on long-term physical and mental health symptoms in people with cystic fibrosis and their caregivers |
K. Hudock, P. Cheng, J. Chmiel, C. Brown, E. Kramer, V. Indihar, et al. (+4) E. Kopras, E. Aliaj, J. Hudson, S. Filigno |
13 |
[GO] |
2022―Oct―03 |
295 Measuring caregiver stress and perceived self-efficacy during a worldwide pandemic |
A. Delecaris, S. Bilinski, K. Walsh, K. Jones |
14 |
[GO] |
2022―Oct―03 |
314 Cystic fibrosis legal information hotline: A reliable resource for the cystic fibrosis community during the pandemic and beyond |
B. Sufian, J. Passamano, A. Sopchak |
15 |
[GO] |
2022―Oct―03 |
316 Depression and anxiety scores after highly effective cmodulator therapy in pandemic times in an adult cystic fibrosis clinic |
J. Blackwelder, V. Indihar, J. Finke, A. Oder, J. Riddle, M. Meyers, et al. (+4) E. Kopras, M. Khawar, B. Meyer, L. Vonbokern |
16 |
[GO] |
2022―Oct―03 |
366 Attitudes amidst the pandemic: Virtual delivery of care in an adult cystic fibrosis population |
A. Thomas-Diceman, X. Ma, Z. Gryz, S. Swaleh, J. Sykes, S. Stanojevic, A. Stephenson |
17 |
[GO] |
2022―Oct―03 |
445 Inflammation in normal COVID-19 airway due to inhibition of cystic fibrosis transmembrane conductance regulator signaling by the SARSCoV-2 Spike protein |
H. Caohuy, O. Eidelman, T. Chen, Q. Yang, N. Walton, H. Pollard |
18 |
[GO] |
2022―Oct―03 |
534 COVID-19 in people with cystic fibrosis and the general population: Severity and virus-host cell interactions |
C. Colombo, G. Alicandro, A. Bandera, V. Bouché, A. Biffi, M. Boraso, et al. (+9) D. Cacchiarelli, F. Ciciriello, M. Cipolli, A. Gramegna, T. Itri, V. Lucidi, P. Medino, C. Rosazza, L. Galietta |
19 |
[GO] |
2022―Oct―03 |
532 Humoral and cell-mediated responses to BNT162b2 mRNA vaccine against SARS-CoV-2 in people with cystic fibrosis |
V. Daccò, L. Cariani, G. Alicandro, C. Rosazza, B. Orena, F. Ferraro, et al. (+3) C. Lanfranchi, M. Liporace, C. Colombo |
20 |
[GO] |
2022―Oct―03 |
485 Chronic sequelae of SARS-CoV-2 in the Scnn1b-Tg mouse model of cystic fibrosis lung disease |
P. Hawkins, W. Anderson, S. Leist, K. Okuda, A. Schaefer, R. Gilmore, et al. (+8) M. Chua, A. Volmer, H. Dang, R. Pickles, A. Livraghi-Butrico, R. Baric, W. O'Neal, R. Boucher |
21 |
[GO] |
2022―Oct―03 |
385 Mechanisms by which cystic fibrosis transmembrane conductance regulator may influence SARS-CoV-2 infection |
P. Tedbury, C. Manfredi, J. Conway, M. Horwath, C. McCracken, A. Sorscher, et al. (+17) S. Moreau, C. Wright, C. Edwards, J. Brewer, J. Guarner, E. De Wit, B. Williamson, Y. Ong, J. Roback, D. Alter, F. Degenhardt, T. Karlsen, A. Franke, S. Sarafianos, E. Sorscher, J. Hong, A. Ehrhardt |
22 |
[GO] |
2022―Oct―03 |
433 Differential small ribonucleic acid expression analysis reveals transforming growth factor beta role in SARS-CoV-2 infection of the cystic fibrosis airway |
E. Hejenkowska, N. Mitash, J. Donovan, F. Mu, D. Beer Stolz, C. Bertrand, A. Swiatecka-Urban |
23 |
[GO] |
2022―Oct―03 |
439 Cystic fibrosis transmembrane conductance regulator impairment strongly decreases SARS-CoV-2 replication in human bronchial epithelial cells |
C. Sorio, V. Lotti, F. Merigo, A. Lagni, A. Di Clemente, M. Ligozzi, et al. (+7) P. Bernardi, G. Rossini, E. Concia, R. Plebani, M. Romano, A. Sbarbati, D. Gibellini |
24 |
[GO] |
2022―Oct―03 |
509 Cystic fibrosis transmembrane conductance regulator positively regulates angiotensin-converting enzyme 2 expression and SARS-CoV-2 viral entry into airway epithelial cells: Implications for patients with cystic fibrosis |
V. Bezzerri, V. Gentili, C. Boni, E. Baldisseri, A. Finotti, C. Papi, et al. (+14) A. Tamanini, D. Olioso, A. Polimeni, S. Leo, M. Borgatti, S. Volpi, P. Pinton, G. Cabrini, R. Gambari, F. Blasi, G. Lippi, A. Rimessi, R. Rizzo, M. Cipolli |
25 |
[GO] |
2022―Sep―16 |
Clinical outcomes of adults and children with cystic fibrosis during the COVID-19 pandemic |
Mr Michael Doumit, Sandra Chuang, Peter Middleton, Hiran Selvadurai, Sheila Sivam, Rasa Ruseckaite, et al. (+5) Susannah Ahern, Kylie Ann Mallitt, Verity Pacey, Kelly Gray, Adam Jaffe |
26 |
[GO] |
2022―Jun―13 |
Factors associated with clinical progression to severe COVID-19 in people with cystic fibrosis: a global observational study |
Siobhán B Carr, Elliot McClenaghan, Alexander Elbert, Albert Faro, Rebecca Cosgriff, Olzhas Abdrakhmanov, et al. (+31) Keith Brownlee, Pierre-Régis Burgel, Catherine A Byrnes, Stephanie Cheng, Carla Colombo, Harriet Corvol, Géraldine Daneau, Christopher H Goss, Vincent Gulmans, Hector Gutierrez, Satenik Harutyunyan, Meagan Helmick, Andreas Jung, Nataliya Kashirskaya, Edward McKone, Joel Melo, Peter G Middleton, Pedro Mondejar-Lopez, Isabelle de Monestrol, Lutz Nährlich, Rita Padoan, Megan Parker, M Dolores Pastor-Vivero, Samar Rizvi, Rasa Ruseckaite, Marco Salvatore, Luiz Vicente R F da Silva-Filho, Nick Versmessen, Marco Zampoli, Bruce C Marshall, Anne L Stephenson |
27 |
[GO] |
2022―Jun―10 |
WS20.02 Input supporting a young person with increased cough suppression in the context of COVID-19 |
A. Shayle, K. Lock |
28 |
[GO] |
2022―Jun―10 |
ePS4.07 COVID-19 early vaccination campaign in Italian cystic fibrosis (CF) patients: the experience of the Italian Society for the Study of Cystic Fibrosis (SIFC) |
F. Lucca, V. Carnovale, R. Casciaro, I. Comello, V. Daccò, E. Ferrara, et al. (+12) M. Francalanci, A. Gramegna, M.C. Lucanto, M. Maschio, B. Messore, G. Pisi, P. Poli, U. Pradal, N. Rotolo, D. Salvatore, P. Vitullo, M. Cipolli |
29 |
[GO] |
2022―Jun―10 |
ePS4.03 Outcomes of COVID-19 in patients with cystic fibrosis in Wales, UK |
D. Lau, L. Speight, F. Melindo, A. Prosser, J. Lee, C. Addy, et al. (+2) J. Duckers, I. Ketchell |
30 |
[GO] |
2022―Jun―10 |
P054 Severity of COVID-19 infection in cystic fibrosis patients compared to the general population |
C. Rosazza, P. Medino, A. Bandera, M.S. Boraso, F. Ciciriello, M. Cipolli, et al. (+7) L.J. Galietta, A. Gramegna, T. Itri, V. Lucidi, A. Biffi, G. Alicandro, C. Colombo |
31 |
[GO] |
2022―Jun―10 |
ePS1.03 The impact of the COVID-19 lockdown and introduction of precision medication Symkevi and Orkambi on cystic fibrosis patients at Sheffield Children’s NHS Foundation Trust, UK (SCFT) |
K. Braisdell, N.S. West |
32 |
[GO] |
2022―Jun―10 |
ePS1.02 Long-term psychological impact of COVID-19 on adult patients with cystic fibrosis, including transplanted patients |
T. Havermans, N. Seyen, K. Luyckx, R. Vos, L. Dupont |
33 |
[GO] |
2022―Jun―10 |
ePS1.05 Impact of COVID-19 on mental health among people with cystic fibrosis |
E.-A. Chrysochoou, E. Hatziagorou, C. Michailidou, M. Gioulvanidou, M. Galogavrou, J. Tsanakas |
34 |
[GO] |
2022―Jun―10 |
ePS4.02 Impact of COVID-19 on the disease course in cystic fibrosis? A Registry-based study |
J. Vandekerckhove, S.S. Wanyama, G. Daneau, L. Peeters, E. DeWachter |
35 |
[GO] |
2022―Jun―10 |
ePS1.04 Sleep disturbances in children with cystic fibrosis at the beginning and in the first year of the COVID-19 pandemic |
T. Sismanlar Eyuboglu, A.T. Aslan, T. Ramasli Gursoy, P. Asfuroglu, A.S. Soysal, D. Yapar, M.N. Ilhan |
36 |
[GO] |
2022―Jun―10 |
ePS4.04 Evaluation of burden of the COVID-19 pandemic among the cystic fibrosis community in Brno, Czech Republic |
M. Mala, L. Homola, E. Pokojova, N. Stastna, A. Holcikova, Z. Gracova |
37 |
[GO] |
2022―Jun―10 |
P256 Change in the anxiety levels of children with cystic fibrosis and their mothers at the beginning of the COVID-19 pandemic and after 1 year |
P. Asfuroglu, T. Sismanlar Eyuboglu, A. Tana Aslan, T. Ramasli Gursoy, B. Pinar Senkalfa, S. Soysal, et al. (+2) D. Yapar, M. Necmi Ilhan |
38 |
[GO] |
2022―Jun―10 |
P188 Vitamin D status at Bristol Adult CF Centre (BACFC) during the COVID-19 pandemic and following the introduction of the multivitamin Paravit CF |
A. Keele, J. Read, F. Hameed, D. Bhaskaran, M. Yousif, K. Bateman |
39 |
[GO] |
2022―Jun―10 |
ePS1.06 Evolution of psychological distress during progression of the COVID-19 pandemic in adults with cystic fibrosis |
F. Cresta, R. Ciprandi, C. Castellani, R. Pescini, R. Casciaro, I. Schiavetti |
40 |
[GO] |
2022―Jun―10 |
P077 Vaccination of patients with cystic fibrosis during the COVID-19 pandemic in Croatia |
I. Markelić, T. Odobašić Palković, I. Bambir, T. Milinković, D. Tješić-Drinković, A. Vukić Dugac |
41 |
[GO] |
2022―Jun―10 |
P184 An evaluation of virtual Cystic Fibrosis-Related Diabetes (CFRD) clinics in the adult service during the COVID-19 pandemic in Northern Ireland (NI) |
E. Molloy, O. Holmes, D. O’Neill, J. Rendall, A. Nugent |
42 |
[GO] |
2022―Jun―10 |
P073 Observed impact on admissions during the COVID-19 pandemic of paediatric cystic fibrosis patients in a tertiary hospital setting |
S. Warraich, K. Lock, C. Hamilton, L. Selby |
43 |
[GO] |
2022―Jun―10 |
P257 Who’s talking about cystic fibrosis continued: the effects of the COVID-19 pandemic on the cystic fibrosis online landscape |
H. Ibrahim, T. Vagg, N.J. Ronan, M. McCarthy, C. Fleming, J. Dorgan, et al. (+3) Y. McCarthy, S. Tabirca, B.J. Plant |
44 |
[GO] |
2022―Jun―10 |
ePS1.07 Parental experiences of face-to-face versus virtual cystic fibrosis clinics during the COVID-19 pandemic: questionnaire study |
K. Lock, L. Lowndes, Z. Johnstone, W. Kozlowska |
45 |
[GO] |
2022―Jun―10 |
P076 COVID-19 vaccination in children and adolescents with cystic fibrosis - a single-centre experience |
A. Zver, M. Praprotnik, M. Aldeco, D. Lepej, S. Šetina Šmid, J. Rodman Berlot, U. Krivec |
46 |
[GO] |
2022―Jun―10 |
ePS4.09 COVID-19 vaccination in households of paediatric cystic fibrosis patients - experience of The Cystic Fibrosis Centre in Zagreb, Croatia |
I. Bambir, I. Todoric, L. Omerza, T. Milinkovic, I. Markelic, T. Odobasic Palkovic, et al. (+2) A. Vukic Dugac, D. Tjesic-Drinkovic |
47 |
[GO] |
2022―Jun―10 |
P075 COVID-19 vaccination uptake in patients with cystic fibrosis |
D.-E. Manning, L. Speight, A. Prosser, J. Duckers |
48 |
[GO] |
2022―Jun―10 |
ePS4.08 COVID-19 vaccine uptake in adult people with cystic fibrosis |
M.H. Mir, T. FitzMaurice, D. Wat, G. Aldous, D. Nazareth, M. Walshaw |
49 |
[GO] |
2022―Jun―10 |
ePS4.05 Evolving cystic fibrosis care during COVID-19: a single-centre experience |
G. Spoletini, C. Campbell, C. Etherington, K. Pollard, N. Burke, D. Shimmin, et al. (+2) I. Clifton, D. Peckham |
50 |
[GO] |
2022―Jun―10 |
WS20.06 Co-infection with Nocardia farcinia and SARS-CoV-2 causing the death of an adolescent with cystic fibrosis |
J. Chapman, F. Gilchrist, S. Driscoll, K. Bakewell, R. Fishwick, S.-A. Ho, W. Carroll |
51 |
[GO] |
2022―Jun―10 |
ePS4.06 Antibody response to administration of 2 doses of the BNT162b2 vaccine against SARS-CoV-2 in people with cystic fibrosis |
G. Alicandro, V. Dacco’, L. Cariani, M. Contarini, C. Rosazza, C.S. Sciarrabba, et al. (+3) F. Ferraro, B.S. Orena, C. Colombo |
52 |
[GO] |
2022―Jun―10 |
P072 SARS-CoV-2 infection in patients with cystic fibrosis (CF) - a single centre experience |
A. Vidoevska, T. Jakovska, S. Momchilovik, I. Arnaudova-Danevska, E. Ginovska-Tasevska |
53 |
[GO] |
2022―Jun―10 |
WS05.04 SARS-CoV-2 infection is reduced in both immortalised and primary CFTR-modulated human bronchial epithelial cells |
V. Lotti, F. Merigo, A. Lagni, A. Di Clemente, M. Ligozzi, P. Bernardi, et al. (+7) G. Rossini, E. Concia, R. Plebani, M. Romano, A. Sbarbati, C. Sorio, D. Gibellini |
54 |
[GO] |
2022―Jun―10 |
ePS4.01 The impact of the SARS-CoV-2 pandemic on people with cystic fibrosis (CF) in Ireland: did individuals maintain their key health outcomes? |
H. Rees, S. Babu, R. Doherty, G. Fletcher, S. Joshy, P. O’Regan, L. Kirwan |
55 |
[GO] |
2022―Jun―10 |
ePS4.10 Evaluation of possible adverse events in relationship to the SARS-CoV-2 vaccination in cystic fibrosis patients with or without lung transplantation: a retrospective single-centre case series |
F. Gautschi, R. Hage, C. Steinack, M.M. Schuurmans |
56 |
[GO] |
2022―Apr―14 |
Immunogenicity of the COVID-19 BNT162b2 vaccine in adolescents and young adults with cystic fibrosis |
Athanasios Michos, Filippos Filippatos, Elisabeth-Barbara Tatsi, Charilaos Dellis, Vasiliki Efthymiou, Ioanna Zarkada, et al. (+3) Evgenia Troupi, Vasiliki Syriopoulou, Ioanna Loukou |
57 |
[GO] |
2022―Feb―21 |
THE CLINICAL IMPACT OF THE COVID-19 PANDEMIC FIRST WAVE ON PATIENTS WITH CYSTIC FIBROSIS IN NEW YORK] |
Joseph L. Simonson, Christine Esposito, Theresa Frantzen, Katherine Henthorne, Aileen Espinal, Serena Romano, et al. (+27) Ramona Ramdeo, Jessica Trentacoste, Donna Tsang, Geralyn La Vecchia, Robert Abdullah, Maria Berdella, Lynn Bonitz, Rany Condos, Andrei Constantinescu, Joan K. DeCelie-Germana, Emily DiMango, Myah Draine, Tara Gimeli, Robert Giusti, Jessenia Guzman, Soumia Hammouda, Claire Keating, Catherine Kier, Alison T. Lennox, Carmen Liriano, Zachary Messer, Amy Plachta, Hossein Sadeghi, Elinor Schwind, Teresa Stables-Carney, Patricia Walker, Janice Wang |
58 |
[GO] |
2022―Feb―16 |
Safety of mRNA-based vaccines against SARS-CoV-2 in people with cystic fibrosis aged 12 years and over |
Gianfranco Alicandro, Valeria Daccó, Lisa Cariani, Martina Contarini, Letizia Corinna Morlacchi, Chiara Rosazza, et al. (+7) Calogero Sathya Sciarrabba, Federica Ferraro, Chiara Lanfranchi, Beatrice Silvia Orena, Andrea Gramegna, Francesco Blasi, Carla Colombo |
59 |
[GO] |
2021―Dec―18 |
Impact of COVID-19 on mental health: Effects on screening, care delivery, and people with cystic fibrosis |
Beth A. Smith, Anna M. Georgiopoulos, Amy Mueller, Janice Abbott, Paula Lomas, Enid Aliaj, Alexandra L. Quittner |
60 |
[GO] |
2021―Dec―18 |
Impact of COVID-19 on mental health: Effects on screening, care delivery, and people with cystic fibrosis (Commentary) |
Trudy Havermans |
61 |
[GO] |
2021―Dec―18 |
Patient and family experience of telehealth care delivery as part of the CF chronic care model early in the COVID-19 pandemic |
George M. Solomon, Julianna Bailey, James Lawlor, Peter Scalia, Gregory S. Sawicki, Christopher Dowd, et al. (+2) Kathryn A. Sabadosa, Aricca Van Citters |
62 |
[GO] |
2021―Dec―18 |
Design and methods for understanding the state of cystic fibrosis care amid the COVID-19 pandemic |
Christopher Dowd, Aricca D. Van Citters, Olivia Dieni, Anne Willis, Leslie Powell, Kathryn A. Sabadosa |
63 |
[GO] |
2021―Dec―18 |
Evaluating barriers to and promoters of telehealth during the COVID-19 pandemic at U.S. cystic fibrosis programs |
Alex H. Gifford, Thida Ong, Christopher Dowd, Aricca D. Van Citters, Peter Scalia, Kathryn A. Sabadosa, Gregory S. Sawicki |
64 |
[GO] |
2021―Dec―18 |
Financial impacts of the COVID-19 pandemic on cystic fibrosis care: lessons for the future |
Gregory S. Sawicki, Aricca D. Van Citters, Olivia Dieni, Kathryn A. Sabadosa, Anne Willis, Debbie Benitez, et al. (+2) Thida Ong, Elliott C. Dasenbrook |
65 |
[GO] |
2021―Dec―18 |
Financial impacts of the COVID-19 pandemic on cystic fibrosis care: Lessons for the future (Commentary) A.L. Stephenson |
Anne L. Stephenson |
66 |
[GO] |
2021―Dec―18 |
Barriers and facilitators to implementing telehealth services during the COVID-19 pandemic: A qualitative analysis of interviews with cystic fibrosis care team members |
Aricca D. Van Citters, Olivia Dieni, Peter Scalia, Christopher Dowd, Kathryn A. Sabadosa, Jill D. Fliege, et al. (+3) Manu Jain, Robert W. Miller, Clement L. Ren |
67 |
[GO] |
2021―Dec―18 |
Impact of the COVID-19 pandemic: How our response is shaping the future of cystic fibrosis care |
Kathryn A. Sabadosa, Albert Faro, Eugene C. Nelson, Bruce C. Marshall |
68 |
[GO] |
2021―Dec―18 |
Telehealth use in cystic fibrosis during COVID-19: Association with race, ethnicity, and socioeconomic factors |
Dana Albon, Aricca D. Van Citters, Thida Ong, Olivia Dieni, Christopher Dowd, Anne Willis, et al. (+5) Kathryn A. Sabadosa, Peter Scalia, Kimberly Reno, Gabriela R. Oates, Michael S. Schechter |
69 |
[GO] |
2021―Dec―13 |
SARS-CoV-2 antibodies among people with cystic fibrosis prior to the vaccination campaign: a seroprevalence study in two specialized centres in Northern Italy |
Gianfranco Alicandro, Valeria Daccó, Lisa Cariani, Martina Contarini, Letizia Corinna Morlacchi, Chiara Rosazza, et al. (+6) Calogero Sathya Sciarrabba, Federica Ferraro, Beatrice Silvia Orena, Andrea Gramegna, Francesco Blasi, Carla Colombo |
70 |
[GO] |
2021―Nov―14 |
Management of Cystic Fibrosis during COVID-19: Patient Reported Outcomes based remote follow-up among CF patients in Denmark - A feasibility study |
Lotte Rodkjær, Majbritt Jeppesen, Liv Schougaard |
71 |
[GO] |
2021―Oct―19 |
76: Sustaining routine cystic fibrosis care in a large pediatric CF program during COVID-19 |
R. Gordon, K. Barnico, G. Sawicki, M. Harrison |
72 |
[GO] |
2021―Oct―19 |
152: Weekly patient-family-staff-volunteer during COVID-19 |
G. Raissi, N. Patel, R. Casey, B. Corcoran, H. Sadeghi |
73 |
[GO] |
2021―Oct―19 |
335: Greater access to mental health care with CF team psychologist through telemedicine during COVID-19 |
S. Filigno, E. Hente, M. Lisa, C. Siracusa |
74 |
[GO] |
2021―Oct―19 |
58: Seroprevalence of COVID-19 IgG in the cystic fibrosis population |
K. Mahan, J. Billings, S. Kiel, S. Sultan, J. Dunitz, B. Noren, et al. (+2) M. Bailey, K. Yun |
75 |
[GO] |
2021―Oct―19 |
346: Tennessee cystic fibrosis clinical care during the COVID-19 pandemic |
F. Cacho, S. Srinivasan, R. Schoumacher, R. Hamilton, J. Ledbetter, M. Moser, et al. (+8) J. Callison, R. Mathes, D. Quintero, A. Metcalf, S. Eastman, J. Tolle, S. Rushing, R. Brown |
76 |
[GO] |
2021―Oct―19 |
334: Addressing food insecurity and mental health during the COVID-19 pandemic |
L. Weaver, M. Reed, A. Chidekel |
77 |
[GO] |
2021―Oct―19 |
310: Physically distant but virtually together: CF community-based webcasts during the COVID-19 pandemic |
A. Uluer, S. Rits, C. Snell, M. Alao, I. Bailey, C. Huysman, et al. (+10) L. Ratner, J. Nash, A. Becker, L. Cardoni, A. Janes, K. Shin, L. McMahon, J. Kennedy, M. Cernadas, R. Cagnina |
78 |
[GO] |
2021―Oct―19 |
296: Mental health implications of genetic modulator therapy in CF: Depression and anxiety screening for pediatric patients prescribed elexacaftor/tezacaftor/ivactor during the COVID-19 pandemic |
T. Vance, M. Finch, D. Bauer, M. Sachs, S. Landvik, J. McNamara |
79 |
[GO] |
2021―Oct―19 |
274: Creating a virtual CF support group for adolescents during the COVID-19 pandemic |
E. Jorgensen, Z. Held, S. Garcha, C. Courtlandt, D. Schellhase |
80 |
[GO] |
2021―Oct―19 |
269: Food security and nutritional adherence in adolescents with cystic fibrosis during the COVID-19 pandemic |
K. Durkin, J. Kelleher, L. Stark, K. Griffin, C. Lynn, S. Filigno, et al. (+4) R. Everhart, D. Fedele, K. Moffett-Bradford, C. Duncan |
81 |
[GO] |
2021―Oct―19 |
239: Perspectives of people with CF and caregivers regarding medication access and telehealth in CF care during the COVID-19 pandemic |
H. Phan, E. Hall Lipsy, K. McCulley, E. Vuong, K. Anderson, A. Sharpe, A. Bowen |
82 |
[GO] |
2021―Oct―19 |
188: Cystic fibrosis kidney stone disease in the era of CFTR modulator use and the COVID-19 pandemic |
S. Romano, T. Frantzen, G. LaVecchia, J. Wang |
83 |
[GO] |
2021―Oct―19 |
177: Impact of elexacaftor/tezacaftor/ivacaftor therapy use on pulmonary exacerbation rates during the COVID-19 pandemic |
E. Menten, T. Saroya, E. DiMango, C. Keating |
84 |
[GO] |
2021―Oct―19 |
166: Reliability of a home spirometer for monitoring children with cystic fibrosis during the COVID-19 pandemic |
D. Mager, C. James-Boldewijn, D. Archangel, S. Lever, H. Janssens |
85 |
[GO] |
2021―Oct―19 |
113: Addressing food insecurity among patients with CF during the COVID-19 pandemic |
W. Sewell, D. Sadeghi, G. Raissi, B. Corcoran, H. Sadeghi |
86 |
[GO] |
2021―Oct―19 |
110: Real-world outcomes in cystic fibrosis telehealth clinical care during the COVID-19 pandemic |
L. Somerville, R. List, M. Compton, H. Bruschwein, D. Jennings, R. Murray, et al. (+5) E. Starheim, K. Webb, J. Kalmanek, L. Gettle, D. Albon |
87 |
[GO] |
2021―Oct―19 |
107: A new statewide consortium of cystic fibrosis care centers formed during the COVID-19 pandemic |
S. Srinivasan, R. Brown, J. Ledbetter, D. Quintero |
88 |
[GO] |
2021―Oct―19 |
83: CF Global Care: Continuation of the collaboration between 2 CF centers; University of Michigan, USA, and Marmara University, Istanbul, Turkey, in the COVID-19 pandemic |
S. Nasr, Y. Gökdemir, E. Erdem Eralp, F. Karakoc, P. Ergenekon, C. Tapley, et al. (+5) S. Dagher, S. Bouma, Ö. Kenisş Cosşkun, D. Kocamaz, F. Karakoc |
89 |
[GO] |
2021―Oct―19 |
79: A patient satisfaction survey regarding the use of telemedicine for outpatient CF endocrinology and diabetes care during the COVID-19 pandemic |
S. Soltman, D. Gardner, A. Swift |
90 |
[GO] |
2021―Oct―19 |
14: Pregnancy and outcomes in the era of CFTR modulators and COVID-19 pandemic |
S. Li, A. Patel, J. Heintz, A. Nance, A. Rice, K. Sakellaris, et al. (+5) S. Gemma, S. Pedigo Blanton, M. Johnson, E. Stephan, S. Kirkby |
91 |
[GO] |
2021―Oct―19 |
44: Characterizing the COVID-19 pandemic among Canadians living with cystic fibrosis: A Canadian Cystic Fibrosis Registry study |
S. Cheng, T. Le, M. McIlwaine, I. McIntosh, J. Wallenburg, A. Stephenson |
92 |
[GO] |
2021―Oct―19 |
314: The COVID-19 pandemic and trends in anxiety and depressive symptoms in adolescents with cystic fibrosis and their caregivers |
S. Szentpetery, K. Foil, L. Christon |
93 |
[GO] |
2021―Oct―19 |
71: Collection of expectorated sputum or oral pharyngeal cultures during initial period of the COVID-19 pandemic in a pediatric cystic fibrosis clinic |
J. Hamilton, S. Meihls, H. Toledo, A. Snuggerud, S. Spade Warren |
94 |
[GO] |
2021―Oct―19 |
333: Perceptions of telehealth of patients with cystic fibrosis and their caregivers during the COVID-19 pandemic in Australia |
R. Ruseckaite, J. Herdiman, S. Ahern |
95 |
[GO] |
2021―Oct―19 |
276: Effects of COVID-19 pandemic on adult cystic fibrosis patients’ mental health |
P. Chen, D. Finklea, L. Cohen, R. Jain, K. Lowe, G. Ratti, et al. (+2) J. Becker, J. Reisch |
96 |
[GO] |
2021―Oct―19 |
41: COVID-19 pandemic restrictions have long-term impact on physical activity in adults with cystic fibrosis |
T. Radtke, S. Haile, H. Dressel, C. Benden |
97 |
[GO] |
2021―Oct―19 |
131: Home spirometry utilization in telemedicine clinic for cystic fibrosis care during COVID-19 pandemic: A quality improvement process |
M. Compton, R. List, E. Starheim, L. Williamson, D. Jennings, L. Gettle, et al. (+4) R. Murray, L. Somerville, H. Bruschwein, D. Albon |
98 |
[GO] |
2021―Oct―19 |
266: Physiotherapy during the COVID-19 pandemic: Support for the shielding patient by the shielding physiotherapist |
J. Carson, L. Alexander, J. Bell |
99 |
[GO] |
2021―Oct―19 |
235: COVID-19 vaccination in individuals with cystic fibrosis at a pediatric cystic fibrosis center |
E. Elson, E. Meier, P. Capel, J. Haynes, M. Fischer, S. Duehlmeyer, C. Oermann |
100 |
[GO] |
2021―Oct―19 |
54: Evaluating COVID-19 Vaccine Hesitancy at the New Orleans Adult CF Care Center |
J. Bodnar, E. Sheffield, R. Klingsberg, C. Bojanowski |
101 |
[GO] |
2021―Oct―19 |
340: Challenges in obtaining COVID-19 vaccines: Bridging the gap for rural northeast Texas cystic fibrosis patients |
C. Guthrie, T. Sadler, C. Wadle, E. Dohanich, L. Couch |
102 |
[GO] |
2021―Oct―19 |
337: Food insecurity in the cystic fibrosis care center network during COVID-19: Prevalence, screening, and interventions |
J. Bailey, G. Brown, M. Corbera-Hincapie, C. Clemm, E. Dasenbrook, D. Durham, et al. (+5) G. Oates, K. Reno, S. Sapp, M. Schechter, K. Robinson |
103 |
[GO] |
2021―Oct―19 |
336: Compass trends and the potential impact of coronavirus |
R. Scott, B. McCreery-Cullifer, K. Muldowney, A. Stocks, A. Kaider |
104 |
[GO] |
2021―Oct―19 |
416: Expression of SARS-CoV-2 entry genes is not greater in the nasal mucosa of CF patients |
M. Sala, N. Markov, A. Misharin, M. Jain |
105 |
[GO] |
2021―Oct―19 |
382: SARS-CoV-2 induces distinct inflammatory signals in cystic fibrosis macrophages that are seduced by resolvins |
A. Recchiuti, S. Patruno, D. Mattoscio, E. Isopi, A. Pomilio, R. Pecce, M. Romano |
106 |
[GO] |
2021―Oct―19 |
496: Reduced susceptibility of mice with CF-like lung disease to SARS-CoV-2 infection |
P. Hawkins, K. Okuda, S. Leist, A. Schafër, R. Gilmore, A. Volmer, et al. (+6) M. Chua, A. Livraghi-Butrico, W. O’Neal, R. Baric, R. Boucher, R. Pickles |
107 |
[GO] |
2021―Oct―19 |
25: Seroprevalence and clinical characteristics of SARS-CoV-2 infection in children and adolescents with cystic fibrosis |
G. Hergenroeder, J. Cogen, A. Genatossio, S. McNamara, M. Pascual, R. Hernandez |
108 |
[GO] |
2021―Oct―19 |
159: Lung function changes following Sars-CoV-2 infection in cystic fibrosis |
T. Kremer, I. St Onge, M. Trivedi, F. Dy, C. Bielick, D. Fish, et al. (+3) O. Schaefer, J. Longtine, K. Longtine |
109 |
[GO] |
2021―Oct―19 |
490: A prospective study to evaluate serologic and immune responses to SARS-COV-2 infection in persons living with cystic fibrosis: Canadian arm of the CAR-CF study |
A. Blanchard, S. Hewko, R. Somayaji, J. Cogen, R. Hernandez, A. Stephenson, et al. (+6) Y. Yau, J. Julien, B. Quon, D. Downey, L. Hoffman, V. Waters |
110 |
[GO] |
2021―Oct―19 |
433: Rationale and design of an international multicenter prospective study to evaluate serologic immune responses to SARS-CoV-2 infection in persons living with cystic fibrosis: The CAR-CF study |
R. Hernandez, J. Cogen, A. Blanchard, V. Waters, D. Downey, L. Hoffman, et al. (+10) S. Hewko, B. Quon, Y. Yau, A. Stephenson, J. Julien, L. Dupont, H. Groves, S. van Koningsbruggen-Rietschel, N. Simmonds, R. Somayaji |
111 |
[GO] |
2021―Oct―19 |
515: Pathways balancing SARS-COV-2 infectivity and disease severity in CF |
S. Nakano, K. Okuda, C. Edwards, H. Dang, T. Asakura, T. Kato, et al. (+12) Y. Mikami, G. Chen, L. Sun, P. Hawkins, R. Gilmore, L. Morton, C. Ribeiro, R. Pickles, S. Randell, W. O’Neal, R. Baric, R. Boucher |
112 |
[GO] |
2021―Oct―19 |
410: Pseudomonas aeruginosa modulates SARS-CoV-2 infectivity in CF airway epithelial cells by increasing expression of the host protease TMPRSS2 |
M. Ruffin, J. Bigot, C. Calmel, J. Mercier, A. Pizzorno, M. Rosa-Calatrava, et al. (+4) H. Corvol, V. Balloy, O. Terrier, L. Guillot |
113 |
[GO] |
2021―Oct―19 |
343: Impact of the SARS-CoV-2 pandemic and a food pantry on food insecurity in a pediatric cystic fibrosis center |
H. Holzum, K. Nelson, J. Granneman, J. Acton, R. Nevel |
114 |
[GO] |
2021―Oct―19 |
156: Pre-procedural Sars-CoV-2 testing and pulmonary function testing |
I. St Onge, F. Dy, M. Trivedi, J. Longtine, K. Longtine, D. Fish, et al. (+3) C. Bielick, O. Schaefer, T. Kremer |
115 |
[GO] |
2021―Oct―19 |
81: Maintaining routine cystic fibrosis sputum surveillance during the pandemic |
J. Seguin, J. Cary, T. Hatch, P. Scharoun, A. Grzymkowski, C. Fortner, et al. (+2) Z. Soultan, S. Joshi |
116 |
[GO] |
2021―Oct―19 |
61: Improving CFRD screening in a pediatric CF center during a pandemic |
J. Stewart, A. Snuggerud, S. Meihls, S. Spade Warren, H. Toledo, F. Asfour |
117 |
[GO] |
2021―Oct―19 |
299: Stress and mental health in cystic fibrosis 1 year after the COVID pandemic: Findings from an Italian sample |
S. Graziano, F. Boldrini, V. Lucidi, P. Tabarini |
118 |
[GO] |
2021―Oct―19 |
344: Initiating food insecurity screening during a pandemic: Identifying and overcoming barriers |
J. Fulton, M. Koons, H. Torres, A. Gray, S. Martin, J. Hoppe |
119 |
[GO] |
2021―Oct―19 |
338: A serendipitous role of telehealth in postpandemic CF care |
J. Makhija, S. Samantha, C. Forseen, V. Taskar, J. Yap |
120 |
[GO] |
2021―Sep―24 |
Digital healthcare in cystic fibrosis. Learning from the pandemic to innovate future care |
J Stuart Elborn |
121 |
[GO] |
2021―Sep―11 |
Telehealth after the pandemic: Will the inverse care law apply? |
Rebecca J Calthorpe, Alan R. Smyth |
122 |
[GO] |
2021―Sep―02 |
Commentary on: “Evaluating barriers and promotors of telehealth during the COVID-19 pandemic at cystic fibrosis programs to inform new models of CF care” |
Sarath C. Ranganathan |
123 |
[GO] |
2021―Jun―11 |
P088 Impact of COVID-19 and cocooning on employment of people with cystic fibrosis |
R. Bhatnagar, S. Tecklenborg, R. Segurado, P. Fitzpatrick |
124 |
[GO] |
2021―Jun―11 |
P179 Has COVID-19 affected the management of vitamin D status amongst people with cystic fibrosis? |
A. Ochota, S. Pandya, M. Walshaw |
125 |
[GO] |
2021―Jun―11 |
P227 Cystic fibrosis social workers’ experience of working during COVID-19 |
F. Dowdall, A. Tansinda, M. Donnelly, S. Chandran |
126 |
[GO] |
2021―Jun―11 |
EPS1.03 Recommended shielding against COVID-19 impacts physical activity levels and adherence to airway clearance therapy in patients with cystic fibrosis |
E. Hatziagorou, P. Peftoulidou, I. Toulia, E. Tasika, E.-A. Chrysochoou, J. Tsanakas |
127 |
[GO] |
2021―Jun―11 |
EPS1.04 Audit of virtual exercise class during COVID-19 in children with cystic fibrosis |
Z. Johnstone, J. Hyson |
128 |
[GO] |
2021―Jun―11 |
P089 Coronavirus infection (COVID-19) in children with cystic fibrosis of the Russian Federation |
E. Kondratyeva, A. Gorelov, E. Zhekaite, S. Nikolaeva, V. Sherman, O. Simonova, et al. (+4) Y. Gorinova, E. Boitsova, M. Mukhina, V. Ledneva |
129 |
[GO] |
2021―Jun―11 |
P137 COVID-19 in cystic fibrosis patients with and without lung transplantation: the Zurich cohort |
C. Steinack, R. Hage, F. Gautschi, M.M. Schuurmans |
130 |
[GO] |
2021―Jun―11 |
P208 Anxiety, depression and resilience during COVID-19 in Dutch patients with cystic fibrosis or primary ciliary dyskinesia and their caregivers |
M. Verkleij, L. Noij, S. Hashimoto, S. Terheggen-Lagro, J. Altenburg, E. Haarman |
131 |
[GO] |
2021―Jun―11 |
P086 The impact of COVID-19 in people with cystic fibrosis - a single-centre experience |
G. Aldous, N. Pinnock, D. Nazareth, M. Walshaw |
132 |
[GO] |
2021―Jun―11 |
P136 Relationship between cystic fibrosis disease severity and susceptibility to COVID-19 infection |
M. Atalay, N. Emiralioĝlu, U. Özçelik, E. Yalçın, D. Doĝru, N. Kiper, D. Dayangaç Erden |
133 |
[GO] |
2021―Jun―11 |
EPS2.07 How did the COVID-19 lockdown influence the nutritional status and body composition of cystic fibrosis patients in Poland? |
M. Mielus, M. Surowiecka, P. Madej, K. Zybert, D. Sands |
134 |
[GO] |
2021―Jun―11 |
EPS1.07 Impact of COVID-19 on cystic fibrosis physiotherapy outpatient clinics |
E. Scott, M. Ledson, M. Walshaw |
135 |
[GO] |
2021―Jun―11 |
P085 Impact of COVID-19 on hospital services and specialist care of adults with cystic fibrosis |
R. Bhatnagar, S. Tecklenborg, R. Segurado, P. Fitzpatrick |
136 |
[GO] |
2021―Jun―11 |
P087 Impact of COVID-19 on mental health of children with cystic fibrosis and their parents |
R. Bhatnagar, S. Tecklenborg, R. Segurado, P. Fitzpatrick |
137 |
[GO] |
2021―Jun―11 |
EPS1.02 The impact of COVID-19 on the prescribing practice of specialist cystic fibrosis physiotherapist non-medical prescribers in the UK |
C. Brown, M. Archer, L. Carson, N. Collins, T. Daniels, A. Gates, et al. (+4) Z. Johnstone, N. Patel, R. Rashid, J.L. Whitehouse |
138 |
[GO] |
2021―Jun―11 |
P232 The impact of COVID-19 on the relationships between parents of young people diagnosed with cystic fibrosis and the cystic fibrosis multidisciplinary team |
S. Jones, L. Smith, K. Ainsworth |
139 |
[GO] |
2021―Jun―11 |
P229 Children and young people with cystic fibrosis enhanced multidisciplinary pathways to address their educational needs during the evolving COVID-19 pandemic |
S. Chandran, M. Panayi |
140 |
[GO] |
2021―Jun―11 |
P230 A review of paediatric cystic fibrosis care during the COVID-19 pandemic |
L. Powell, J. Watkinson, N. Rao |
141 |
[GO] |
2021―Jun―11 |
P226 A survey of family experience of cystic fibrosis care during the COVID-19 pandemic |
J. Watkinson, L. Powell, N. Rao |
142 |
[GO] |
2021―Jun―11 |
P225 Parents’ feedback on virtual paediatric cystic fibrosis clinics during COVID-19 pandemic |
M. Powell, R. Rees, L. John, R. Street, R. Evans |
143 |
[GO] |
2021―Jun―11 |
P218 Detection of anxiety and depression through mental health screening questionnaires in cystic fibrosis patients and their families during the COVID-19 pandemic |
A. Morales Tirado, E. Blitz Castro, S. Vicente Santamaría, A. Lamas Ferreiro, M.F. Pando, P. Fernández Martín, et al. (+6) M. Garriga García, D. San Miguel Simonín, A. Sayagués Vega, S. Jarillo Martín, R.M. Nieto Royo, L. Máiz Carro |
144 |
[GO] |
2021―Jun―11 |
P211 Use of telemedicine for mental health screening during the COVID-19 pandemic |
H. Bruschwein, M. Soper, D. Jennings, L. Somerville, R. List, M. Compton, et al. (+4) L. Gettle, R. Murray, E. Starheim, D. Albon |
145 |
[GO] |
2021―Jun―11 |
P172 Patient experience of Manchester Virtual Cystic Fibrosis-Related Diabetes Clinic during the COVID-19 pandemic |
A. Brennan, J. Pickles, S. Punt, K. Taylor, J. Beynon |
146 |
[GO] |
2021―Jun―11 |
P157 Monitoring the distribution and genotypic diversity of Burkholderiales bacteria in Russian cystic fibrosis patients in the year of the COVID-19 pandemic |
O. Voronina, N. Ryzhova, M. Kunda, E. Aksenova, A. Lasareva, O. Simonova, et al. (+3) S. Semykin, E. Amelina, A. Gintsburg |
147 |
[GO] |
2021―Jun―11 |
P138 Rapid implementation of virtual clinics during the COVID-19 pandemic |
D. Nazareth, C. Sumner, M. Walshaw |
148 |
[GO] |
2021―Jun―11 |
P094 Facilitating cystic fibrosis research during the COVID-19 pandemic |
S. Burnett, M. Preidt, T. FitzMaurice, M. Walshaw, D. Nazareth |
149 |
[GO] |
2021―Jun―11 |
P091 Regularity of check-ups at the cystic fibrosis centre in the time of COVID-19 pandemic |
I. Todorić, I. Bambir, I. Markelić, L. Omerza, T. Milinković, T. Odobašić Palković, et al. (+4) F. Džubur, A. Vukić Dugac, D. Tješić-Drinković, D. Tješić-Drinković |
150 |
[GO] |
2021―Jun―11 |
P090 A UK survey on changes in managing people with cystic fibrosis during the COVID-19 pandemic |
M.S. Hameed, A. Kumar, C. Baker, D. Nazareth, M. Walshaw |
151 |
[GO] |
2021―Jun―11 |
EPS1.01 Physiotherapy practice of French cystic fibrosis children changed during lockdown due to COVID-19 pandemic |
M. Mittaine, E. Aversenq, P. Milhorat, C. Lannibois, P. Maumus, A. Arrouy |
152 |
[GO] |
2021―Jun―11 |
WS14.2 Potential factors influencing reduced requirements for intravenous antibiotics during the COVID-19 pandemic |
K. Richards, S. Geoghegan, M. Butler, N. Shafi, D. Watson |
153 |
[GO] |
2021―Jun―11 |
WS11.1 The anxiety levels of children with cystic fibrosis and healthy children during the COVID-19 pandemic |
A.P. Ergenekon, M. Cenk, C. Yilmaz Yegit, M. Yuksel, A. Guliyeva, A. Toksoy Aksoy, et al. (+6) G. Bilicen, Y. Gokdemir, E. Erdem Eralp, A. Rodopman Arman, F. Karakoc, B. Karadag |
154 |
[GO] |
2021―Jun―11 |
EPS1.09 Adapting services during the COVID-19 pandemic - a patient evaluation of physiotherapy telephone reviews within multidisciplinary team virtual clinics |
S. Fitzgerald, C. Lathia, P. Wilson. |
155 |
[GO] |
2021―Jun―11 |
P092 Embedding an electronic patient record into a developing UK service and impact during the COVID-19 pandemic - Blackpool Adult Cystic Fibrosis Service (BACFS) |
N. Pickering, T. Saba |
156 |
[GO] |
2021―Jun―11 |
P223 The role of psychologist in a cystic fibrosis centre during the COVID-19 pandemic - experience of a Polish paediatric centre |
U. Borawska-Kowalczyk, A. Sujecka, M. Mielus, D. Sands |
157 |
[GO] |
2021―Jun―11 |
P141 Has the COVID-19 pandemic affected medication adherence to inhaled nebulised therapy for patients at a large adult cystic fibrosis centre? |
N. Iqbal, Z. Nadat, J.E. Vessey, K.J. Martin, A.L. Brennan, R.J. Bright-Thomas, et al. (+3) H.D. Green, A.M. Jones, P.J. Barry |
158 |
[GO] |
2021―Jun―11 |
P220 Experiences of virtual cystic fibrosis clinics during the COVID-19 pandemic at one UK adult cystic fibrosis centre |
L. Warnock, W. Flight, K. Chapman, A. Gates |
159 |
[GO] |
2021―Jun―11 |
WS14.4 Exploring cystic fibrosis patient and staff perceptions of the Virtual Healthcare Hub during the COVID-19 pandemic at the All Wales Adult Cystic Fibrosis Service |
E. Birkin, C. Bridges, L. Speight, C. O'Leary, J. Duckers |
160 |
[GO] |
2021―Jun―11 |
P221 Quality of life in adult and children with cystic fibrosis during the COVID-19 pandemic in Croatia |
T. Odobasic Palkovic, T. Milinkovic, I. Markelic, F. Džubur, I. Godic, I. Barbir, et al. (+2) D. Tjesic-Drinkovic, A. Vukic-Dugac |
161 |
[GO] |
2021―Jun―11 |
P139 Evaluating the impact of a telemedicine service during the COVID-19 pandemic in people with cystic fibrosis |
A. Bull, T.S. FitzMaurice, D. Nazareth, M. Walshaw |
162 |
[GO] |
2021―Jun―11 |
WS14.1 The effect of the COVID-19 pandemic on quality of life of adults with cystic fibrosis |
E. Birkin, L. Speight, A. Smith, C. Oleary, J. Duckers |
163 |
[GO] |
2021―Jun―11 |
P219 Before and during the COVID-19 pandemic: a review of health of our paediatric cystic fibrosis patients |
L. Powell, J. Watkinson, N. Rao |
164 |
[GO] |
2021―Jun―11 |
P224 Change in care during the COVID-19 pandemic: single-centre experience in a middle-income setting |
E. Hatziagorou, I. Toulia, E. Kalaitzidou, E-A Chrysochoou, M. Galogavrou, J. Tsanakas |
165 |
[GO] |
2021―Jun―11 |
EPS2.04 The role of Flash Glucose Monitoring System at annual review during the COVID-19 restrictions, within Cystic Fibrosis Diabetes Service at Blackpool Adult Cystic Fibrosis Centre, UK |
A. Connolly, J. Knowles, M. Etumi |
166 |
[GO] |
2021―Jun―11 |
EPS3.05 N-chlorotaurine is a very promising antiseptic treatment option for multiresistant bacteria, fungi and for viruses including SARS-CoV-2 |
C. Schwarz, M. Lackner, P. Eschenhagen, M. Nagl |
167 |
[GO] |
2021―Jun―11 |
WS14.5 SARS-CoV-2 driving rapid change in cystic fibrosis services: the role of the clinical nurse specialist |
R. Dunk, S. Madge |
168 |
[GO] |
2021―Jun―11 |
P134 SARS-CoV-2 infection in cystic fibrosis during the first pandemic wave in Italy: a multi-centre prospective study with a control group |
C. Colombo, G. Alicandro, V. Daccó, V. Gagliano, L.C. Morlacchi, R. Casciaro, et al. (+11) G. Pisi, M. Francalanci, A. Cavallo, P. Poli, A. Folino, B. Messore, S. Cristadoro, G. Leonetti, M. Maschio, F. Lucca, M. Cipolli |
169 |
[GO] |
2021―Jun―11 |
P135 SARS-COV-2 infection in patients with cystic fibrosis |
L. Balanetchi, E. Gudumac, D. Rotaru-Cojocari, R. Selevestru, S. Sciuca |
170 |
[GO] |
2021―Jun―11 |
P083 Clinical progression of SARS-CoV-2 infection in people with cystic fibrosis: a global observational study |
E. McClenaghan, R. Cosgriff, K. Brownlee, S. Ahern, P.-R. Burgel, C.A. Byrnes, et al. (+29) C. Colombo, H. Corvol, S.Y. Cheng, G. Daneau, A. Elbert, A. Faro, C.H. Goss, V. Gulmans, H. Gutierrez, I. de Monestrol, A. Jung, L. Nährlich, N. Kashirskaya, B.C. Marshall, E. McKone, P.G. Middleton, P. Mondejar-Lopez, M.D. Pastor-Vivero, R. Padoan, S. Rizvi, R. Ruseckaite, M. Salvatore, A.L. Stephenson, L.V.R. da Silva Filho, J. Melo, M. Zampoli, O. Abdrakhmanov, S. Harutyunyan, S.B. Carr |
171 |
[GO] |
2021―Jun―11 |
P231 Patient experience of accessing a virtual cystic fibrosis service during the 2020 SARS-CoV-2 pandemic in Blackpool, North West of England |
A. Sanderson-Thomas, N. Pickering, T. Saba |
172 |
[GO] |
2021―Jun―11 |
P163 Effects of the SARS-CoV-2 pandemic on attendance at the cystic fibrosis centre and the definition of the microbiological status of cystic fibrosis patients in Tuscany |
D. Dolce, N. Ravenni, M. Francalanci, S. Campana, E. Camera, G. Mergni, et al. (+6) T. Orioli, M.C. Cavicchi, V. Galici, A.S. Neri, V. Terlizzi, G. Taccetti |
173 |
[GO] |
2021―Jun―11 |
P062 Impact of the SARS-CoV-2 pandemic on clinical trials in the ECFS-CTN during 2020 |
S. Van Koningsbruggen-Rietschel, V. Bulteel, F. Dunlevy, K. Hayes, A. Verbrugge, D. Downey |
174 |
[GO] |
2021―Jun―11 |
P084 The impact of the SARS-CoV-2 pandemic on people living with cystic fibrosis in Ireland: real-world data from the Irish cystic fibrosis registry |
H. Rees, S. Babu, G. Fletcher, L. Kirwan |
175 |
[GO] |
2021―Jun―11 |
P222 Supporting children with cystic fibrosis: building social networks through the pandemic |
E. Lee Mindel |
176 |
[GO] |
2021―Jun―11 |
P140 TeCC (TeleMedicine, Cystic Fibrosis, Corona-Virus) study in a previous telemedicine-naive centre: clinical challenges, outcomes, and user experience in the first six months of a global pandemic |
D. Morrissy, T. Vagg, M. McCarthy, J. Dorgan, C. Fleming, C. Howlett, et al. (+2) J.A. Eustace, B.J. Plant |
177 |
[GO] |
2021―Jun―11 |
P051 Rollout of Kaftrio® to adult cystic fibrosis patients at the Royal Brompton Hospital during a global pandemic |
E. Bowman, C. Caldwell, A. Jones, S. Madge |
178 |
[GO] |
2021―Jun―11 |
P203 Fertile ground: pregnancies in a post-Kaftrio® pandemic era |
A. Lillis, S. Lorca-Mayor, P. Weldon, E. Marsh, S. Collins, C. Lathia, et al. (+5) E. Bowman, A. Jones, N. Simmonds, S. Madge, I. Felton. |
179 |
[GO] |
2021―Jun―05 |
Speaking of pandemics... |
Michael S. Schechter |
180 |
[GO] |
2021―Apr―19 |
Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020 |
Naehrlich Lutz, Orenti Annalisa, Dunlevy Fiona, Kasmi Irena, Harutyunyan Satenik, Pfleger Andreas, et al. (+64) Bobrovnichy Vladimir, Keegan Svetlana, Daneau Géraldine, Petrova Guergana, Bambir Ivan, Dugac Vukic Andrea, Tješić-Drinković Duška, Yiallouros Panayiotis, Drevinek Pavel, Macek Milan, Bilkova Alena, Olesen Hanne Vebert, Burgel Pierre- Régis, Corvol Harriet, Lemonnier-Videau Lydie, Parulava Tsitsino, Hatziagorou Elpis, Diamantea Filia, Párniczky Andrea, Fletcher Godfrey, McKone Edward F, Mei-Zahav Meir, Padoan Rita, Salvatore Marco, Colombo Carla, Aleksejeva Elina, Malakauskas Kestutis, Schlesser Marc, Fustik Stojka, Turcu Oxana, Gulmans Vincent, Zomer-van Ommen Domenique, Senstad Wathne Anita, Bakkeheim Egil, Woźniacki Łukasz, Pereira Luísa, Pop Liviu, Kondratyeva Elena, Amelina Elena, Zhekaite Elena, Simonova Olga, Kashirskaya Nataliya, Rodić Milan, Kayserova Hana, Krivec Uros, Mondejar-Lopez Pedro, Pastor-Vivero Maria Dolores, de Monestrol Isabelle, Lindblad Anders, Dogru Deniz, Yasemin Gökdemir, Pekcan Sevgi, Makukh Halyna, Brownlee Keith, Cosgriff Rebecca, McClenaghan Eliott, Carr Siobhán, Lammertyn Elise, Zolin Anna, Fox Alice, Krasnyk Marco, Van Rens Jacqui, van Koningsbruggen-Rietschel Silke, Jung Andreas |
181 |
[GO] |
2021―Apr―16 |
COVID-19 vaccine prioritisation for people with cystic fibrosis |
Siobhán B Carr, Rebecca Cosgriff, Satenik Harutyunyan, Peter G Middleton, Rasa Ruseckaite, Susannah Ahern, et al. (+32) Géraldine Daneau, Luiz Vicente R F da Silva Filho, Anne L Stephenson, Stephanie Y Cheng, Joel Melo, Harriet Corvol, Pierre-Régis Burgel, Lutz Nährlich, Edward McKone, Carla Colombo, Marco Salvatore, Rita Padoan, Olzhas Abdrakhmanov, Vincent Gulmans, Catherine A Byrnes, Elena Amelina, Elena Kondratyeva, Elena Zhekayte, Nataliya Kashirskaya, Marco Zampoli, M Dolores Pastor-Vivero, Pedro Mondejar-Lopez, Isabelle de Monestrol, Andeas Jung, Elliot McClenaghan, Keith Brownlee, Samar Rizvi, Christopher H Goss, Alexander Elbert, Albert Faro, Hector Gutierrez, Bruce C Marshall |
182 |
[GO] |
2021―Apr―08 |
SARS-CoV-2 and Burkholderia cenocepacia infection in a patient with Cystic Fibrosis: an unfavourable conjunction? |
C. Olcese, R. Casciaro, D. Pirlo, C. Debbia, E. Castagnola, F. Cresta, C. Castellani |
183 |
[GO] |
2021―Mar―27 |
Patient and family perceptions of telehealth as part of the cystic fibrosis care model during COVID-19 |
Davis Jaclyn, NeSmith Andrew, Perkins Ryan, Bailey Julianna, Siracusa Christopher, Chaudary Nauman, et al. (+3) M. Powers, Sawicki Gregory S, Solomon George M |
184 |
[GO] |
2021―Jan―26 |
To the Editor of Journal of Cystic Fibrosis: First and second wave of SARS-CoV2 in Italian Cystic Fibrosis patients: data from Italian Cystic Fibrosis Registry |
Rita Padoan, Marco Salvatore |
185 |
[GO] |
2020―Dec―23 |
PSYCHOLOGICAL DISTRESS IN ADULTS WITH AND WITHOUT CYSTIC FIBROSIS DURING THE COVID-19 LOCKDOWN |
Riccardo Ciprandi, Maurizio Bonati, Rita Campi, Rita Pescini, Carlo Castellani |
186 |
[GO] |
2020―Dec―17 |
The impact of SARS-CoV-2 on the cystic fibrosis foundation therapeutics development network |
Kelsie Pearson, Nicole Mayer-Hamblett, Christopher H. Goss, George Z. Retsch-Bogart, Jill M. VanDalfsen, Patricia Burks, et al. (+4) Daniel Rosenbluth, John Paul Clancy, Amy Hoffman, David P. Nichols |
187 |
[GO] |
2020―Dec―03 |
Clinical characteristics of SARS-CoV-2 infection in children with cystic fibrosis: an international observational study |
Robert Bain, Rebecca Cosgriff, Marco Zampoli, Alexander Elbert, Pierre-Régis Burgel, Siobhán B Carr, et al. (+19) Claudio Castaños, Carla Colombo, Harriet Corvol, Albert Faro, Christopher H Goss, Hector Gutierrez, Andreas Jung, Nataliya Kashirskaya, Bruce C Marshall, Joel Melo, Pedro Mondejar-Lopez, Isabelle de Monestrol, Lutz Naehrlich, Maria Dolores Pastor-Vivero, Samar Rizvi, Luiz Vicente Ribeiro Ferreira da Silva Filho, Keith G Brownlee, Iram J Haq, Malcolm Brodlie |
188 |
[GO] |
2020―Nov―20 |
ALPHA-1 ANTITRYPSIN FOR CYSTIC FIBROSIS COMPLICATED BY SEVERE CYTOKINEMIC COVID-19 |
Oliver J McElvaney, Eoin O'Connor, Natalie L McEvoy, Daniel D Fraughan, Jennifer Clarke, Oisín F McElvaney, et al. (+4) Cedric Gunaratnam, James O'Rourke, Gerard F Curley, Noel G McElvaney |
189 |
[GO] |
2020―Nov―05 |
The global impact of SARS-CoV-2 in 181 people with cystic fibrosis |
Elliot McClenaghan, Rebecca Cosgriff, Keith Brownlee, Susannah Ahern, Pierre-Régis Burgel, Catherine A Byrnes, et al. (+27) Carla Colombo, Harriet Corvol, Stephanie Y Cheng, Géraldine Daneau, Alexander Elbert, Albert Faro, Christopher H Goss, Vincent Gulmans, Hector Gutierrez, Isabelle de Monestrol, Andreas Jung, Lutz Nährlich Justus, Nataliya Kashirskaya, Bruce C Marshall, Edward McKone, Peter G Middleton, Pedro Mondejar-Lopez, M Dolores Pastor-Vivero, Rita Padoan, Samar Rizvi, Rasa Ruseckaite, Marco Salvatore, Anne Stephenson, Luiz Vicente R da Silva Filho, Joel Melo, Marco Zampoli, Siobhán B Carr |
190 |
[GO] |
2020―Aug―28 |
Recommended shielding against COVID-19 impacts physical activity levels in adults with cystic fibrosis |
Thomas Radtke, Sarah R. Haile, Holger Dressel, Christian Benden |
191 |
[GO] |
2020―Aug―11 |
SARS-CoV-2 seroprevalence in a belgian cohort of patients with cystic fibrosis |
S. Berardis, A. Verroken, A. Vetillart, C. Struyf, M. Gilbert, D. Gruson, S. Gohy |
192 |
[GO] |
2020―Jul―31 |
The impact of the COVID-19 pandemic on the emotional well-being and home treatment of Belgian patients with cystic fibrosis, including transplanted patients and paediatric patients. |
Trudy Havermans, Janne Houben, Francois Vermeulen, Mieke Boon, Marijke Proesmans, Natalie Lorent, et al. (+3) Erik de Soir, Robin Vos, Lieven Dupont |
193 |
[GO] |
2020―Jun―23 |
No detection of SARS-CoV-2 in cystic fibrosis patients at the Regional (Lazio) Reference Center for CF in Italy |
Carolina Scagnolari, Camilla Bitossi, Federica Frasca, Agnese Viscido, Giuseppe Oliveto, Mirko Scordio, et al. (+6) Corrado De Vito, Maria Trancassini, Fabio Midulla, Giuseppe Cimino, Alessandra Pierangeli, Guido Antonelli |
194 |
[GO] |
2020―Jun―08 |
Healthcare reassessment in a pandemics time: challenges for CF |
Carlo Castellani |
195 |
[GO] |
2020―May―11 |
COVID-19 in lung-transplanted and cystic fibrosis patients: Be careful |
Eric Farfour, Clément Picard, Laurence Beaumont, Philippe Lesprit, Marie-Christine Ballester, Felix Ackermann, et al. (+4) Richard Galliot, Sylvie Colin de Verdiere, Charles Cerf, Marc Vasse |
196 |
[GO] |
2020―Apr―25 |
A MULTINATIONAL REPORT TO CHARACTERISE SARS-CoV-2 INFECTION IN PEOPLE WITH CYSTIC FIBROSIS |
Rebecca Cosgriff, Susannah Ahern, Scott C. Bell, Keith Brownlee, Pierre-Régis Burgel, Cass Byrnes, et al. (+12) Harriet Corvol, Stephanie Y. Cheng, Alexander Elbert, Albert Faro, Christopher H. Goss, Vincent Gulmans, Bruce C. Marshall, Edward McKone, Peter G. Middleton, Rasa Ruseckaite, Anne L. Stephenson, Siobhán B Carr |
197 |
[GO] |
2020―Apr―13 |
Asymptomatic case of Covid-19 in an infant with cystic fibrosis |
Piercarlo Poli, Silviana Timpano, Martina Goffredo, Rita Padoan, Raffaele Badolato |